Sumatriptan succinate is under clinical development by Klaria Pharma Holding and currently in Phase I for Migraine. According to GlobalData, Phase I drugs for Migraine have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sumatriptan succinate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sumatriptan succinate overview
Sumatriptan succinate is under development for the treatment of migraine. The drug candidate is administered by transmucosal and buccal routes. It selectively targets 5-HT1B and 5-HT1D receptors. It is developed based on alginate-based polymer drug delivery technology.
Klaria Pharma Holding overview
Klaria Pharma Holding (Klaria Pharma) is a pharmaceutical company. It develops fast acting medicinal products for the treatment of cannabinoids, migraine, opioid overdose and cancer related pain. The company’s patented drug delivery platform features is an alginate based polymer film which facilitates a quick transmucosal absorption and distribution of the marketed drugs or clinical substances directly to the bloodstream. Klaria Pharma also offers other stable supply forms including nasal sprays and orally dissolvable tablets. It offers its products to customers worldwide through distributors. Klaria Pharma is headquartered in Uppsala, Sweden.
For a complete picture of Sumatriptan succinate’s drug-specific PTSR and LoA scores, buy the report here.